J

Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015

Watchlist Manager
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Watchlist
Price: 156 SAR 4.7%
Market Cap: 10.9B SAR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Jamjoom Pharmaceuticals Factory Company SJSC stock under the Base Case scenario is 154.2 SAR. Compared to the current market price of 156 SAR, Jamjoom Pharmaceuticals Factory Company SJSC is Overvalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
154.2 SAR
Overvaluation 1%
Relative Value
Price
J
Worst Case
Base Case
Best Case

Valuation Multiples

8.3
P/S
P/S
Price to Sales
8.3
vs History
28
vs Industry
17
Median 3Y
8.3
Median 5Y
8.3
Industry
2.4
Forward
7.1
More Details
30.6
P/E
P/E
Price to Earnings
30.6
vs History
28
vs Industry
15
Median 3Y
30.6
Median 5Y
30.6
Industry
20.3
Forward
26.1
More Details
41.5
P/OCF
P/OCF
Price to OCF
41.5
vs History
0
vs Industry
10
Median 3Y
35.2
Median 5Y
35.2
Industry
15.6
More Details
53
P/FCFE
P/FCFE
Price to FCFE
53
vs History
7
vs Industry
10
Median 3Y
43.1
Median 5Y
43.1
Industry
23.1
More Details
7.3
P/B
P/B
Price to Book Value
7.3
vs History
19
vs Industry
9
Median 3Y
6.9
Median 5Y
6.9
Industry
2
More Details
8.1
EV/S
EV/S
Enterprise Value to Sales
8.1
vs History
31
vs Industry
16
Median 3Y
8.1
Median 5Y
8.1
Industry
2.5
Forward
6.9
More Details
13
EV/GP
EV/GP
Enterprise Value to Gross Profit
13
vs History
28
vs Industry
16
Median 3Y
13
Median 5Y
13
Industry
4.8
More Details
25.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
25.5
vs History
31
vs Industry
14
Median 3Y
25.5
Median 5Y
25.5
Industry
12.5
Forward
21.9
More Details
28
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28
vs History
28
vs Industry
16
Median 3Y
28
Median 5Y
28
Industry
15.7
Forward
24.6
More Details
40.5
EV/OCF
EV/OCF
Enterprise Value to OCF
40.5
vs History
7
vs Industry
10
Median 3Y
34.8
Median 5Y
34.8
Industry
14.1
More Details
51.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
51.6
vs History
7
vs Industry
9
Median 3Y
42.5
Median 5Y
42.5
Industry
17.6
More Details
8
EV/IC
EV/IC
Enterprise Value to IC
8
vs History
4
vs Industry
11
Median 3Y
7.6
Median 5Y
7.6
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Jamjoom Pharmaceuticals Factory Company SJSC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
SA
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
10.9B SAR 8.3 30.6 25.5 28
US
Eli Lilly and Co
NYSE:LLY
778.5B USD 15.9 70.1 37.6 41.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.9B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.9 19.8 13.1 14.9
CH
Roche Holding AG
SIX:ROG
216.2B CHF 3.6 26.1 9.8 11.5
UK
AstraZeneca PLC
LSE:AZN
168.2B GBP 4.1 28.7 131 197.5
CH
Novartis AG
SIX:NOVN
181.6B CHF 4.1 17.1 10.1 13.6
US
Merck & Co Inc
NYSE:MRK
209.4B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
120.9B EUR 1.3 9.5 5.2 6.2
P/E Multiple
Earnings Growth PEG
SA
J
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Average P/E: 25.7
30.6
14%
2.2
US
Eli Lilly and Co
NYSE:LLY
70.1
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.8
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.1
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28.7
36%
0.8
CH
Novartis AG
SIX:NOVN
17.1
17%
1
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.5
28%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SA
J
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Average EV/EBIT: 1 699.7
28
13%
2.2
US
Eli Lilly and Co
NYSE:LLY
41.1
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.9
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
197.5
21%
9.4
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.2
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.